Pathophysiological consequences of TAT-HKII peptide administration are independent of impaired vascular function and ensuing ischemia

Rianne Nederlof, Chaoqin Xie, Otto Eerbeek, Anneke Koeman, Dan M.J. Milstein, Markus W. Hollmann, Egbert G. Mik, Alice Warley, Richard Southworth, Fadi G. Akar, Coert J. Zuurbier

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Rationale: We have shown that partial dissociation of hexokinase II (HKII) from mitochondria in the intact heart using low-dose transactivating transcriptional factor (TAT)-HKII (200 nmol/L) prevents the cardioprotective effects of ischemic preconditioning, whereas high-dose TAT-HKII (10 μmol/L) administration results in rapid myocardial dysfunction, mitochondrial depolarization, and disintegration. In this issue of Circulation Research, Pasdois et al argue that the deleterious effects of TAT-HKII administration on cardiac function are likely because of vasoconstriction and ensuing ischemia. Objective: To investigate whether altered vascular function and ensuing ischemia recapitulate the deleterious effects of TAT-HKII in intact myocardium. Methods and Results: Using a variety of complementary techniques, including mitochondrial membrane potential (Δψm) imaging, high-resolution optical action potential mapping, analysis of lactate production, nicotinamide adenine dinucleotide epifluorescence, lactate dehydrogenase release, and electron microscopy, we provide direct evidence that refutes the notion that acute myocardial dysfunction by high-dose TAT-HKII peptide administration is a consequence of impaired vascular function. Moreover, we demonstrate that low-dose TAT-HKII treatment, which abrogates the protective effects of ischemic preconditioning, is not associated with ischemia or ischemic injury. Conclusions: Our findings challenge the notion that the effects of TAT-HKII are attributable to impaired vascular function and ensuing ischemia, thereby lending further credence to the role of mitochondria-bound HKII as a critical regulator of cardiac function, ischemia-reperfusion injury, and cardioprotection by ischemic preconditioning.

Original languageEnglish (US)
Pages (from-to)e8-13
JournalCirculation research
Issue number2
StatePublished - Jan 18 2013
Externally publishedYes


  • TAT peptide
  • hexokinase
  • ischemia
  • mitochondrial membrane potential
  • vasoconstriction

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pathophysiological consequences of TAT-HKII peptide administration are independent of impaired vascular function and ensuing ischemia'. Together they form a unique fingerprint.

Cite this